XML 18 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated statements of profit or loss and other comprehensive income - AUD ($)
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Revenue and other income      
Revenue from continuing operations $ 0 $ 0 $ 15,183,000
Other income 1,000 25,000 2,000
Finance income — bank interest 22,000 2,000 42,000
Expenses      
Research and development expense (15,564,000) (20,169,000) (14,541,000)
General and administrative expense (8,583,000) (5,113,000) (7,020,000)
Gain/(loss) on remeasurement of contingent consideration 3,388,000 0 (2,570,000)
Commercialisation 0 (127,000) 0
Loss before income tax benefit from continuing operations (20,736,000) (25,382,000) (8,904,000)
Income tax benefit 271,000 368,000 484,000
Loss after income tax benefit for the year (20,465,180) (25,014,055) (8,420,000)
Items that may be reclassified subsequently to profit or loss      
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax 110,000 35,000 2,000
Other comprehensive income for the year, net of tax 110,000 35,000 2,000
Total comprehensive income for the year (20,355,000) (24,979,000) (8,418,000)
Loss for the year is attributable to:      
Owners of Kazia Therapeutics Limited (20,465,000) (25,014,000) (8,420,000)
Loss after income tax benefit for the year (20,465,180) (25,014,055) (8,420,000)
Total comprehensive income for the year is attributable to:      
Owners of Kazia Therapeutics Limited (20,355,000) (24,979,000) (8,418,000)
Total comprehensive income for the year $ (20,355,000) $ (24,979,000) $ (8,418,000)
Earnings per share for loss from continuing operations attributable to the owners of Kazia Therapeutics Limited      
Basic earnings per share $ (0.1123) $ (0.1888) $ (0.0716)
Diluted earnings per share (0.1123) (0.1888) (0.0716)
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited      
Basic earnings per share (0.1123) (0.1888) (0.0716)
Diluted earnings per share $ (0.1123) $ (0.1888) $ (0.0716)